Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
89bio, Inc. (ETNB)  
$9.86 0.09 (0.9%) as of 4:30 Fri 6/27


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 161,930,000
Market Cap: 1.60(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $4.83 - $11.66
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 24.2
Insider 3/6 Months : 24.8
Guru Rank Number :  733
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 5,729,285 5,754,285 7,104,285
Total Buy Value $0 $50,099,844 $50,302,794 $71,025,294
Total People Bought 0 2 3 3
Total Buy Transactions 0 3 6 7
Total Shares Sold 15,329 26,292 54,247 173,942
Total Sell Value $91,208 $162,358 $389,353 $1,807,679
Total People Sold 1 1 1 3
Total Sell Transactions 1 2 3 7
End Date 2025-03-30 2024-12-27 2024-06-28 2023-06-29

   
Records found: 232
  Page 1 of 10  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Le-Nguyen Quoc See Remarks   •       –      –    2025-06-12 4 D $9.62 $5,137 I/I (534) 14,216     -
   Le-Nguyen Quoc See Remarks   •       –      –    2025-06-12 4 D $9.62 $81,751 D/D (8,498) 319,825     -
   Martins Ryan Chief Financial Officer   •       –      –    2025-06-12 4 D $9.62 $81,751 D/D (8,498) 261,176     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2025-06-12 4 D $9.62 $81,751 D/D (8,498) 310,336     -
   Le-Nguyen Quoc See Remarks   •       –      –    2025-04-15 4 AS $5.95 $91,208 D/D (15,329) 328,323 63%     
   Le-Nguyen Quoc See Remarks   •       –      –    2025-02-17 4 D $10.57 $11,099 D/D (1,050) 343,652     -
   Martins Ryan Chief Financial Officer   •       –      –    2025-02-17 4 D $10.57 $8,245 D/D (780) 269,674     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2025-02-17 4 D $10.57 $11,099 D/D (1,050) 318,834     -
   Palekar Rohan Chief Executive Officer   •       •      –    2025-02-17 4 D $10.57 $34,342 D/D (3,249) 862,240     -
   Palekar Rohan Chief Executive Officer   •       •      –    2025-02-09 4 D $11.41 $102,074 D/D (8,946) 864,692     -
   Martins Ryan Chief Financial Officer   •       –      –    2025-02-09 4 D $11.41 $43,677 D/D (3,828) 270,454     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2025-02-09 4 D $11.41 $43,552 D/D (3,817) 319,884     -
   Le-Nguyen Quoc See Remarks   •       –      –    2025-02-09 4 D $11.41 $43,278 D/D (3,793) 344,702     -
   Le-Nguyen Quoc See Remarks   •       –      –    2025-02-01 4 A $9.60 $84,000 I/I 8,750 14,750     -
   Martins Ryan Chief Financial Officer   •       –      –    2025-02-01 4 D $9.60 $32,045 D/D (3,338) 274,282     -
   Martins Ryan Chief Financial Officer   •       –      –    2025-02-01 4 A $0.00 $0 D/D 80,000 277,620     -
   Le-Nguyen Quoc See Remarks   •       –      –    2025-02-01 4 D $9.60 $32,045 D/D (3,338) 348,495     -
   Le-Nguyen Quoc See Remarks   •       –      –    2025-02-01 4 A $0.00 $0 D/D 80,000 351,833     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2025-02-01 4 D $9.60 $32,045 D/D (3,338) 323,701     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2025-02-01 4 A $0.00 $0 D/D 80,000 327,039     -
   Sarena Francis Willard Chief Operating Officer   •       –      –    2025-02-01 4 A $0.00 $0 D/D 53,750 78,750     -
   Palekar Rohan Chief Executive Officer   •       •      –    2025-02-01 4 D $9.60 $92,141 D/D (9,598) 873,638     -
   Palekar Rohan Chief Executive Officer   •       •      –    2025-02-01 4 A $0.00 $0 D/D 412,000 883,236     -
   Shah Rajeev M. Director   –       •       •   2025-01-30 4 B $8.75 $49,999,994 I/I 5,714,285 19,554,319 2.25 7%     
   Mcwherter Charles   –       •      –    2025-01-22 4 B $6.71 $67,100 D/D 10,000 25,000 0.01 50%     
  232 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 10
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us